Closing a heart opening to treat drug-resistant epilepsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy and safety of closing the patent foramen ovale (PFO) in patients suffering from drug-resistant epilepsy. The research is based on preliminary findings that suggest a correlation between PFO and epilepsy, with potential improvements in seizure frequency following PFO closure. Participants will undergo a procedure to close the PFO, and their seizure activity will be monitored over time to assess the treatment's effectiveness. The study aims to provide more definitive evidence on whether this intervention can benefit patients who have not responded to traditional epilepsy medications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 60 years, with no gender restrictions;
2. Diagnosis of epilepsy in accordance with the International League Against Epilepsy (ILAE) criteria (2014 edition);
3. Drug-resistant epilepsy, defined as failure to achieve sustained seizure freedom despite appropriate selection and tolerability of at least two antiseizure medications (monotherapy or combination therapy) for a minimum of six months;
4. Diagnosis of patent foramen ovale (PFO) meeting the criteria established by the American Society of Echocardiography (ASE) and the Society for Cardiovascular Angiography and Interventions (SCAI) (2015 edition), with right-to-left shunting (RLS) of grade II or higher upon Valsalva maneuver, as assessed by contrast-enhanced echocardiography;
5. Stable antiseizure medication regimen for at least four weeks prior to screening, with willingness to maintain a stable regimen throughout the study period;
6. At least one documented seizure episode during a six-week screening period (with a minimum of four weeks of effective seizure diary recordings) and a retrospective self-reported history of at least 12 seizures in the year preceding screening;
7. Ability to independently or with caregiver assistance complete a seizure diary and comply with clinical data collection and required medical examinations;
8. Willingness to undergo the investigational treatment and voluntary provision of written informed consent.

Exclusion Criteria:

1. Patients diagnosed with epilepsy of a known etiology, including infectious, metabolic, immune, genetic, or structural causes;
2. History of stroke or psychogenic nonepileptic seizures (PNES);
3. History of epilepsy surgery or implantable neurostimulation therapy, or planned epilepsy surgery, neurostimulation therapy, ketogenic diet therapy, or other antiseizure interventions during the study period;
4. Presence of structural cardiac abnormalities other than patent foramen ovale (PFO), such as moderate or severe valvular regurgitation or pulmonary hypertension;
5. Presence of severe central nervous system (CNS) diseases, including acute cerebrovascular disease, intracranial tumors, intracranial infections, or progressive CNS disorders;
6. Evidence of vascular puncture site infection or difficulty with puncture as assessed by transesophageal echocardiography combined with contrast-enhanced right heart echocardiography;
7. Documented contraindications to antiplatelet therapy;
8. Presence of severe psychiatric disorders, such as schizophrenia, bipolar disorder, or severe depression or anxiety;
9. History of alcohol or other substance abuse;
10. Severe dysfunction of vital organs (heart, lungs, liver, kidneys) deemed by the investigator to pose a risk to the participant or impair the participant's ability to complete the study;
11. Pregnant or breastfeeding women, or women planning to conceive during the study period;
12. Participation in another interventional clinical trial within three months prior to signing the informed consent form, current participation in another interventional trial, or plans to participate in another interventional trial during the study period; inability to comply with follow-up due to travel or relocation;
13. Any other condition that the investigator determines makes the patient unsuitable for participation in this study.

Where it's running

• Westchina Hospital
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Lei Chen
• Email: leilei_25@126.com
• Phone: +8618980605819

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

  This study tests whether low intensity focused ultrasound can help reduce seizures in adults with drug‑resistant epilepsy.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07680842

• Long-term follow-up of the Minder implanted EEG system for epilepsy care

  This follow-up will see if long-term use of the implanted Minder sub‑scalp EEG system helps doctors manage care for people with epilepsy whose seizures are not well captured by standard EEGs.

  Recruiting at 20 sites Epiminder America, Inc. · Birmingham, Alabama and 20 other locations · NCT07110454

• Minder sub‑scalp EEG to improve diagnosis and care for epilepsy

  This test will see if the Minder sub‑scalp EEG device gives more reliable, long‑term seizure data than usual care for people with drug‑resistant epilepsy whose seizures aren't well captured by standard EEG.

  Recruiting at 23 sites Epiminder America, Inc. · Birmingham, Alabama and 22 other locations · NCT07110337

• Biomarker study to predict Vagus Nerve Stimulation response in adults with refractory epilepsy

  This study tests whether biomarkers and network measures can predict how adults with refractory epilepsy will respond to vagus nerve stimulation (VNS) after implantation.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Brussels · NCT07909486

• Cannabidiol as add-on therapy for children with refractory epilepsy (CBD-uN1que): an individualized N-of-1 series

  This trial tests whether CBD oil helps reduce seizures in children with hard-to-treat epilepsy, using a series of personalized N-of-1 comparisons against a placebo.

  Recruiting Phase 3 UMC Utrecht · Utrecht, Utrecht · NCT07668856

• Real-world use of the OneRF Ablation System for epilepsy

  This registry collects real-world outcomes and device performance from patients with drug-resistant epilepsy who are treated with SEEG-guided RF ablation using the OneRF system.

  Recruiting at 3 sites NeuroOne Medical Technologies Corporation · Miami, Florida and 2 other locations · NCT07546253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.